Determine a more efficient and cost effective method for ensuring that monthly antibody testing is being done on all candidates on the wait list for deceased donor kidney, kidney/pancreas and pancreas transplants.
By reaching out to peer HLA labs, we identified two companies that could potentially meet our specific needs, one of them being Path-Tec. We thoroughly investigated offerings from both vendors. We compared several different variables – cost, services offered, reporting tools, reliability, etc. After all the research was complete, our team determined that Path-Tec would be able to meet our unique needs and help us continue to provide our patients and dialysis units the high level of service which they are accustomed.
The project team decided to look specifically at how specimen integrity and sample return rate would be affected by the implementation of the Path-Tec system. The baseline specimen integrity analysis indicated a current rejection rate of 19% (338 total specimens rejected out of 1780 total specimens received). One of the target goals established was to decrease the number of samples rejected by 75%, from 19% to 5% or less. The second target goal identified was to increase the current sample return rate from an average of 50% (1780 samples received out of 3500 kits sent) to a target of 80% or higher. This data would be collected by team members on a monthly basis by monitoring both the Path-Tec website and the HLA lab’s sample registry.
Throughout the course of this process improvement, we implemented rapid change cycles as needed. As we monitored specimen integrity (i.e. samples with no date, samples with no requisition, hemolyzed samples, those with only one identifier) changes were made to the request form three times to assist with specimen integrity and return rate. As of July 2014, we reached our goal of decreasing the rejection rate by 75%. We are meeting our original target of 5% or less rejection rate. Before Path-Tec was implemented, we had an average return rate of approximately 50%. Our average return rate is now approximately 80%. We will continue to track sample rejections and return rate on a monthly basis and improve our process as necessary.
“As an integral business partner and our largest supplier over the last 8 years, we have put the trust of our customers in the hands of Path-Tec and time after time, they have delivered. Our business has grown double digits over the past two consecutive years and Path-Tec has risen to the occasion without hesitation. From quality products and customer service excellence to collaboration and execution on new opportunities, Path-Tec has been and continues to be part of our success and a true business partner.”
“After comparing several vendors, our team determined that Path-Tec would best meet our unique needs as we continue to provide our patients and dialysis units the high level of service to which they are accustomed. We are now meeting our original target of 5% or less rejection rate. Path-Tec has helped us improve our return rate nearly 60%. This has greatly improved client satisfaction levels and has proven to be a great return on our investment.”
“Path-Tec’s technology platform is highly advanced, extremely user-friendly, and has provided a complete set of client and specimen management tools for us to utilize. SpectraPath has helped us reduce waste and increase efficiency beyond our expectations.”
“As an integral business partner, we have put the trust of our customers in the hands of Path-Tec and time after time, they have delivered. From quality products and customer service excellence to collaboration and execution on new opportunities, Path-Tec has been and continues to be part of our success and a true business partner.”